Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Syndax Pharmaceuticals, Inc. SNDX
$20.75
+$0.31 (1.49%)
На 18:00, 12 мая 2023
+81.54%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1393491336.00000000
-
week52high
29.86
-
week52low
13.27
-
Revenue
0
-
P/E TTM
-9
-
Beta
1.11418600
-
EPS
-2.54000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Buy | Buy | 09 авг 2022 г. |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| HC Wainwright & Co. | Buy | 11 апр 2022 г. | |
| Goldman Sachs | Buy | 15 февр 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 12 окт 2021 г. |
| JP Morgan | Overweight | 03 янв 2023 г. | |
| HC Wainwright & Co. | Buy | Buy | 12 дек 2022 г. |
| Goldman Sachs | Buy | Buy | 12 дек 2022 г. |
| Stifel | Buy | 31 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Goldan Keith A. | A | 110000 | 110000 | 02 февр 2023 г. |
| Madigan Catherine | A | 110000 | 110000 | 02 февр 2023 г. |
| Morrison Briggs | A | 32000 | 32000 | 02 февр 2023 г. |
| Metzger Michael A | A | 410000 | 410000 | 02 февр 2023 г. |
| Ordentlich Peter | A | 90000 | 90000 | 02 февр 2023 г. |
| Podlesak Dennis | A | 107763 | 32000 | 02 февр 2023 г. |
| Nolte Alexander | A | 17000 | 17000 | 02 февр 2023 г. |
| Jarrett Jennifer | A | 48000 | 16000 | 02 февр 2023 г. |
| Katkin Keith | A | 48000 | 16000 | 02 февр 2023 г. |
| Legault Pierre | A | 48000 | 16000 | 02 февр 2023 г. |
Новостная лента
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Call Transcript
Seeking Alpha
08 мая 2023 г. в 22:53
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President and Head of R&D Keith Goldan - Chief Financial Officer Dr. Anjali Ganguli - Chief Business Officer Conference Call Participants Madhu Kumar - Goldman Sachs Eva Privitera - TD Cowen Anupam Rama - JPMorgan Yigal Nochomovitz - Citigroup Peter Lawson - Barclays Kalpit Patel - B. Riley Securities Joel Beatty - Baird Dara Azar - Stifel Justin Zelin - BTIG Operator Good day, everyone, and welcome to the Syndax First Quarter 2023 Earnings Conference Call.
Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023
PRNewsWire
01 мая 2023 г. в 07:00
WALTHAM, Mass. , May 1, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2023 financial results and provide a business update on Monday, May 8, after the close of the U.S. financial markets.
Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why
Zacks Investment Research
06 февр 2023 г. в 10:32
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Syndax (SNDX) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research
20 янв 2023 г. в 10:32
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Are You Looking for a Top Momentum Pick? Why Syndax Pharmaceuticals (SNDX) is a Great Choice
Zacks Investment Research
18 янв 2023 г. в 13:33
Does Syndax Pharmaceuticals (SNDX) have what it takes to be a top stock pick for momentum investors? Let's find out.